Changes in seizure susceptibility after intracerebral treatment with 5,7-dihydroxytryptamine: role of serotonergic neurons.
D015116:5,7-Dihydroxytryptamine / Q000494:pharmacology*; D000086:Acetazolamide / Q000494:pharmacology; D000818:Animals; D000927:Anticonvulsants; D004102:Dihydroxytryptamines / Q000494:pharmacology*; D004597:Electroshock; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D010433:Pentylenetetrazole / Q000494:pharmacology; D010634:Phenobarbital / Q000494:pharmacology; D010672:Phenytoin / Q000494:pharmacology; D011903:Raphe Nuclei / Q000502:physiology; D051381:Rats; D012640:Seizures / Q000503:physiopathology*; D012701:Serotonin / Q000502:physiology*
D000927:Anticonvulsants; D004102:Dihydroxytryptamines; D015116:5,7-Dihydroxytryptamine; D012701:Serotonin; D010672:Phenytoin; D000086:Acetazolamide; D010433:Pentylenetetrazole; D010634:Phenobarbital